Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Condition:   Non Small Cell Lung Cancer Intervention:   Sponsor:   Hunan Province Tumor Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Semin Respir Crit Care Med 2020; 41: 400-408 DOI: 10.1055/s-0040-1710077Traditionally, lung cancer has been treated as an immune-resistant disease with platinum-based chemotherapy serving as the first-line treatment for metastatic disease. The efficacy of immunotherapy has been established for patients with advanced lung cancer in clinical trials, and it has since become the standard of care for patients without targetable mutations, with or without chemotherapy. Previously, lung cancer patients experienced limited responses to immune-based therapy. As clinical trials continued to explore immunotherapy options with checkpo...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Abstract Chemotherapy and targeted therapy have significantly improved the progression of non-small cell lung cancer (NSCLC), but patients are inevitably suffering from drug resistance and relapse. With this background, the immunotherapy brings a turnaround for a subset of cancer patients. Over two decades, with the development of immunotherapy, immune checkpoint inhibitors (ICIs) have made a breakthrough in NSCLC patients. ICIs targeting the programmed death 1 receptor (PD-1), programmed cell death receptor ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) showed significantly antitumor ef...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth, early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have extensive-stage (ES) disease, defined as the presence of metastatic disease outside the hemithorax at first diagnosis. SCLC has been considered “a graveyard for drug development,” with chemotherapy remaining the standard treatment for first- and second-line management until quite recently. In contrast to NSCLC, identifying therapeutic targets in SCLC has been challenging, partly because driver mutations are primarily loss of functio...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionOur findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumour aberrations.“We are pleased to offer people with certain types of lung cancer a new chemothera...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Abstract Lung cancer is currently the highest morbidity and mortality malignancy all over the world. In the past, the treatment options available for patients with lung cancer were mainly chemotherapy and tyrosine kinase inhibitors, but after a period of treatment, cancer cells inevitably developed resistance. With the elucidation of the immune escape mechanism of tumor cells recently, immunotherapy, especially immune checkpoint inhibitors, has shown unparalleled advantages in cancer treatment, becoming a new hope for cancer patients after multi-line treatment failure. Immune checkpoint inhibitors usually belong t...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Conclusions: 18F-FDG PET/CT performed before the start of immunotherapy might be an important prognostic tool able to predict the disease progression and response to immunotherapy in patients with advanced NSCLC, since MTV, TLG and radiomics features (volume and heterogeneity) are associated with disease progression.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a breakthrough in lung cancer treatment. The efficacy of monoclonal antibodies targeting the programmed cell death protein 1 (PD-1), its ligand L1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways has been demonstrated in several randomized trials, at first as second line therapy, then as first line with or without combination with chemotherapy, resulting in significantly improved survival rates in lung cancer patients, especially those with advanced non-small-cell lung cancer (NSCLC), compared to standard chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSION: The application of ICIs could result in a higher incidence and relative risk of all grade immune-induced liver dysfunction. Moreover, immunotherapy combined with chemotherapy may also increase relative risk of all grade hepatic AEs when compared with monotherapy. Prompt recognition and proper administration is required for clinicians to prevent potentially hepatic deterioration. PMID: 32371246 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
Conclusion: Our case report presents a novel pattern of RRP induced by anti-PD-1 blockade Camrelizumab 2 years after radiotherapy. This indicates that previous radiotherapy combined with subsequent anti-PD-1 blockade has a potential to cause overlapping damage to lung, suggesting that intensive attention might be needed for patients who are treated with anti-PD-1 blockade in conjunction with a prior history of thoracic radiation.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Immunotherapy | Non-Small Cell Lung Cancer | Research